Dentsply SironaXRAY
XRAY
About: Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
Employees: 14,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
60% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $7.89M
15% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 110
7% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 57
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
1% less funds holding
Funds holding: 356 [Q4 2024] → 353 (-3) [Q1 2025]
1.43% less ownership
Funds ownership: 100.84% [Q4 2024] → 99.41% (-1.43%) [Q1 2025]
22% less capital invested
Capital invested by funds: $3.81B [Q4 2024] → $2.96B (-$850M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
2%
upside
Avg. target
$21
32%
upside
High target
$25
60%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Barrington Research Michael Petusky | 34%upside $21 | Outperform Maintained | 12 May 2025 |
UBS Kevin Caliendo | 60%upside $25 | Buy Maintained | 9 May 2025 |
Piper Sandler Jason Bednar | 2%upside $16 | Neutral Maintained | 30 Apr 2025 |
Financial journalist opinion
Based on 25 articles about XRAY published over the past 30 days
Neutral
Accesswire
3 days ago
Dentsply Sirona Inc. (XRAY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
Neutral
Zacks Investment Research
3 days ago
Is the Options Market Predicting a Spike in Dentsply Sirona Stock?
Investors need to pay close attention to XRAY stock based on the movements in the options market lately.
Positive
Zacks Investment Research
4 days ago
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dentsply Sirona Inc. (XRAY) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
Neutral
Accesswire
6 days ago
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Dentsply Sirona Inc. and Encourages Long-Term Dentsply Investors to Contact the Firm - XRAY
PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Dentsply Sirona Inc. (NASDAQ:XRAY) ("Dentsply") on behalf of the company's long-term investors. Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/case/dentsply-sirona/ Recently an amended securities fraud complaint was filed against Dentsply on behalf of investors who purchased shares of the company's stock between June 9, 2021 and November 13, 2022.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Dentsply Sirona Inc. (XRAY) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
Neutral
GlobeNewsWire
1 week ago
Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes
CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced it has priced an offering (the “Offering”) of $550 million aggregate principal amount of its 8.375% Junior Subordinated Notes due 2055 (the “notes”).
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dentsply Sirona Inc. (XRAY) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
Positive
Seeking Alpha
1 week ago
Buying Dentsply Sirona
I'm changing my tune on XRAY and buying at current levels due to its cheap valuation and attractive risk premium over Treasuries. Despite sluggish recent financials, the balance sheet is solid with ample cash and a sustainable dividend, making the stock less risky now. Key headwinds are likely fading, and an aging population could provide a tailwind for future growth, supporting a speculative buy.
Neutral
Accesswire
1 week ago
Dentsply Sirona Inc. (XRAY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
Charts implemented using Lightweight Charts™